Selective ASO-based JAK2 inhibitor for the treatment of hematological malignancies with JAK2 V617F mutation burden. Use of causal modeling to uncover cell-cell communication dynamics in the tumor ...
US pharma major AbbVie and China’s RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational programmed cell ...
Inhaled KB707, a novel HSV-based immunotherapy, as a monotherapy in patients with advanced solid tumor malignancies affecting the lungs: Efficacy and safety results from a phase 1/2 study. Completed ...
In the fight against disease, programmed cell death – also known as apoptosis – is a key protective function of the body. It breaks down cells that are damaged or have undergone dangerous changes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results